Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04606316 · ClinicalTrials.gov registry record · Phase 1

Surgical Nivolumab And Ipilimumab For Recurrent GBM

A Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Patrick Wen, MD.

Active
Registry status
Phase 1
Development phase
63
Enrollment target
4
Study locations

NCT04606316 is a Phase 1 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by Patrick Wen, MD. The registered enrollment target is 63 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (42% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04606316, a Phase 1 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by Patrick Wen, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
63 participants
Enrollment target
4
Study locations

Study Summary

This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab * Placebo (IV solution with no medicine) * Zr-89 Crefmirlimab berdoxam (optional sub-study)

Conditions Studied

Glioblastoma Glioblastoma Multiforme GBM Grade IV Astrocytoma

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • PROCEDURE Surgery
  • DRUG Nivolumab-Placebo
  • DRUG Ipilimumab-Placebo

Study Locations (4)

California

  • University of California Los Angeles - Los Angeles
  • Stanford University - Stanford

Massachusetts

  • Dana Farber Cancer Institute - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2021-02-01
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Patrick Wen, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04606316

The ClinicalTrials.gov registry entry for NCT04606316 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (42% lower). The listed sponsor is Patrick Wen, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.

NCT04606316 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT04606316 about?

NCT04606316 is a clinical study titled "Surgical Nivolumab And Ipilimumab For Recurrent GBM". This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab * Placebo (IV solution with no medicine) * Zr...

What is the current status of trial NCT04606316?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2021-02-01. Estimated completion is 2026-12-31.

What conditions does trial NCT04606316 study?

This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, GBM, Grade IV Astrocytoma.

What interventions are being tested in trial NCT04606316?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Surgery (PROCEDURE), Nivolumab-Placebo (DRUG), Ipilimumab-Placebo (DRUG).

Who is sponsoring clinical trial NCT04606316?

This trial is sponsored by Patrick Wen, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04606316 being conducted?

This trial has 4 study locations across California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Glioblastoma Multiforme

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.